机译:40个国家的抗癌生物纤维单模可用性
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Dept Med Oncol Beijing;
Natl Med Prod Adm Ctr Drug Evaluat Beijing Peoples R China;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Off Canc Screening Beijing;
Capital Med Univ Beijing Tiantan Hosp China Natl Clin Res Ctr Neurol Dis Clin Trial Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Pfizer Investment Shanghai Peoples R China;
Nanjing Med Univ Affiliated Huaian Peoples Hosp 1 Phase Clin Trial Ctr 1 Huaian Peoples R China;
Huludao Cent Hosp Huludao Canc Qual Control Ctr Huludao Peoples R China;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Off Canc Screening Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Clin Trials Ctr Beijing;
Chinese Acad Med Sci Canc Hosp Natl Clin Res Ctr Canc Natl Canc Ctr Dept Thorac Surg Beijing;
机译:40个国家的抗癌生物纤维单模可用性
机译:淡紫色试验和抗癌生物素描的盛开
机译:欧盟药物检测对抗癌生物仿生单克隆抗体的监管要求
机译:生成可用性数据系统(GADS):简化报告过程并对齐NERC GAD可用性报告与IEC 61400-26报告(PPT)
机译:中全新生软体动物可用性和在中间田纳西州的使用:以网站40DV7为例
机译:小儿克罗恩氏病的抗肿瘤坏死因子疗法:通过优化治疗提高收益更深入地了解其风险并由于生物仿制药的使用而降低成本
机译:发达国家生物仿制药的供应引发的PR1价格差异
机译:钛在市场经济国家的可用性:矿产可用性评估